Vaccine Acceptance

Nurses play an important role in providing vaccine information and supporting informed vaccination decisions. This study will evaluate a digital educational intervention designed for registered nurses in Quebec. The intervention will provide education about vaccination, including immunology, epidemiology, vaccine communication, motivational interviewing, and responding to vaccine misinformation. Registered nurses will be randomly assigned to either the intervention group or a control group. The study will examine whether the intervention improves vaccine confidence and vaccine communication compared with the control group. Participants will complete questionnaires before and after the intervention, with follow-up assessments at 3 and 6 months. The study will assess vaccine hesitancy and changes in vaccine-related knowledge, communication skills, and vaccination recommendation practices. The findings will help determine whether a digital educational intervention can support nurses in their vaccine-related communication and professional practice.

This study looks at a digital platform that supports HPV vaccination in schools. The goal is to see if it is useful, easy to use, and practical in real school settings, especially in areas where fewer people get vaccinated. Researchers will give Year 5 pupils (aged 11-12) and their parents or caregivers access to the platform. It provides clear, trusted information about the HPV vaccine for young people, parents, and school nurses. The aim is to make the vaccine easier to understand and to help answer any questions or concerns. After using the platform, participants will be asked to share their thoughts.

This is a Phase I/IIa, randomized, double-blind, placebo-controlled, dose-escalation clinical trial to test the candidate vaccine StreptInCor. The study will include four different doses (25 µg, 50 µg, 100 µg, and 200 µg) of StreptInCor produced under Good Manufacturing Practices (GMP) and formulated with aluminum hydroxide as the vaccine adjuvant. The adjuvant alone will be used as a placebo in this trial. Five groups, each consisting of twelve healthy adult volunteers, will randomly receive two doses of the vaccine or placebo with a 28-day interval, along with a booster dose six months after the initial vaccination